Format

Send to

Choose Destination
J Infect Dis. 2019 Sep 26;220(9):1498-1502. doi: 10.1093/infdis/jiz353.

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia.

Author information

1
Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
2
BioAegis Therapeutics, North Brunswick, New Jersey.

Abstract

Therapy to enhance host immune defenses may improve outcomes in serious infections, especially for antibiotic-resistant pathogens. Recombinant human plasma gelsolin (rhu-pGSN), a normally circulating protein, has beneficial effects in diverse preclinical models of inflammation and injury. We evaluated delayed therapy (24-48 hours after challenge) with rhu-pGSN in a mouse model of pneumococcal pneumonia. rhu-pGSN without antibiotics increased survival and reduced morbidity and weight loss after infection with either penicillin-susceptible or penicillin-resistant pneumococci (serotypes 3 and 14, respectively). rhu-pGSN improves outcomes in a highly lethal pneumococcal pneumonia model when given after a clinically relevant delay, even in the setting of antimicrobial resistance.

KEYWORDS:

antibiotic-resistance; immunomodulation; plasma gelsolin; pneumonia

PMID:
31287867
PMCID:
PMC6761947
[Available on 2020-09-26]
DOI:
10.1093/infdis/jiz353

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center